BioPharmCatalyst

🚨 New Podcast Drop! 🎙️ The first episode of Biotech Bulls & Breakthroughs is live! Brought to you by BioPharmCatalyst, we’re diving into the latest moves in the biotech market with special guest Sheff from @SheffStation 🎧️ Episode: "Tariffs, GLP-1 Trends & Sheff's Catalyst…

BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Fall 2025 $ZYNE $ENTA $RLYB $KALA $ASMB $CAPR $RPTX $ASMB $XCUR biopharmcatalyst.com/news/2025/key-…

$ LYEL entered a private placement with institutional and accredited investors to raise up to $100 million ($50 million upfront) by selling shares at $13.32, funding LYL314 CAR-T trials, a planned Phase 3 lymphoma study, a solid-tumor program, and general operations, extending…

$PHIO signed a US drug‑substance development and CGMP manufacturing deal for its lead INTASYL siRNA candidate PH‑762, securing analytical/process development and clinical‑grade supply to advance its intratumoral Phase 1b dose‑escalation trial See More Pre-market Movers 👇…

$NVCR reported Q2 2025 revenue of $159M, up 6% year-over-year, with 4,331 active patients on therapy. EPS was $(0.36), beating the $(0.39) estimate, and sales of $158.8M exceeded the $153.9M estimate. See More Biotech Updates👇 biopharmcatalyst.com/news/2025/immu… $IPA $NVCR $MRSN $GLPG…

$GLPG reported that its first quarter 2025 results show consistent revenues of €140.3M but a significant 91% surge in R&D expenses to €278M. Overall expenses (G&A, S&M) rose 23% to €74.5M. This led to a net loss of €259.1M, a stark contrast to Q1 2024's €99.2M profit.…

$CLSD announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema (UME). See More Biotech Updates👇 biopharmcatalyst.com/news/2025/abiv… $ABVX $ANEB $CLSD $IMNN $GHRS $PHVS $IOVA $LTRN

$ANEB announced a proposed reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500 as part of a plan to go private by reducing its number of shareholders. Stockholders with fewer than the minimum required shares post-split will be cashed out at $3.50 per pre-split…

$ABVX shares are halted following results that its 50mg obefazimod achieved 16.4% pooled placebo-adjusted clinical remission at 8 weeks in Phase 3 ABTECT induction trials for moderate-to-severe UC, meeting all key secondary endpoints with favorable safety. Maintenance data is due…

$REPL received a Complete Response Letter from the FDA for its BLA for RP1 with nivolumab in advanced melanoma, citing the IGNYTE trial as inadequate due to patient heterogeneity and confirmatory trial design issues; no safety concerns were noted. Replimune plans to request a…

$PMN shares closed up after the company announced that PMN310, its lead therapeutic candidate for Alzheimer's, received FDA Fast Track designation. See More Biotech Updates👇 biopharmcatalyst.com/news/2025/zimv… $PMN $ZIMV $EVO $SABS $HOOK $SLRX $CLSD $GDTC

$ITOS to be acquired by Concentra Biosciences for $10.047/share in cash plus a CVR tied to net cash above $475M and potential asset sales; tender offer to begin by Aug 1, 2025. See More Pre-market Movers 👇 biopharmcatalyst.com/news/2025/prom… $PMN $HSDT $ZIMV $SABS $NCNA $AUTL $EVO

BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Mid-2025 $REPL $OTLK $RARE $WINT $ATAI $CYBN $IXHL $TNXP $VYNE $ATHE $PFE $CRDF $PRAX biopharmcatalyst.com/news/2025/key-…

$SRPT shares closed down 36% at $14.08 following a Bloomberg report detailing a patient's death from acute liver failure in an early-stage gene-therapy study. This incident adds to two previous Elevidys-related fatalities currently under FDA review. See More Biotech Updates👇…

$TELO reported promising data for Telomir-1, which showed it could reverse epigenetic gene silencing and restore tumor suppressors in human prostate cancer cells, outperforming chemotherapy and rapamycin. See More Pre-market Movers 👇 biopharmcatalyst.com/news/2025/telo… $MESO $CNSP $SRPT…

$CLSD initiated a strategic review to explore options including asset sales, partnerships, or M&A to advance its SCS platform; Piper Sandler retained to lead the process. See More Biotech Updates👇 biopharmcatalyst.com/news/2025/wind… $WINT $SRPT $RCKT $FOLD $MBRX $CLSD $ICU

Want an edge in biotech trading? In this new pod, Sheff and John cover: 🧬 Biotech investment strategies 📉 Market trends 🚨 Upcoming plays worth watching A must-listen for small-cap hunters → youtu.be/6aVtN0Oc1CI #PharmaStocks #DueDiligence

$WINT signed a $60M securities purchase agreement led by Build and Build Corp, with the potential to raise a total of $200M, to launch a BNB crypto treasury strategy. Subject to shareholder approval, Windtree aims to become the first NASDAQ-listed company offering direct BNB…